Navigation Links
Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer's Disease Drug Treatment Program
Date:1/20/2011

PITTSBURGH, Jan. 20, 2011 /PRNewswire/ -- Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.  

New investors in the A1 financing include The Breedlove Limited Family Partnership and TMC Investment Company, an investment division of the Tippins family, both located in Pittsburgh.  All existing investors participated in the round including Ogden CAP Associates, M5Invest, the Pittsburgh Life Sciences Greenhouse and Innovation Works.  The round was comprised of new investment and conversion of convertible debt.  

"This financing increases our investor base and further expands our national network to support the critical work we are doing to identify drugs that can treat and potentially prevent the progression of Alzheimer's disease," said Cognition Therapeutics President and CEO Hank Safferstein, Ph.D., J.D.  "We're pleased to welcome Golden Seeds, Tech Coast Angels and several western Pennsylvania community leaders in supporting our pioneering approach to drug discovery for Alzheimer's disease and related conditions of the central nervous system.  We are also fortunate to have Dr. Nada Jain, Managing Director of Golden Seeds and Mr. Mark Breedlove, President and CEO of Keystone Profiles, joining our existing Board of Directors, providing additional business insight and guidance to the company."

"The drug candidates Cognition Therapeutics is developing represent new approaches that have the potential to make a major impact on the treatment of Alzheimer's disease, and other central nervous system disorders," said Dr. Jain.  "The company has received positive peer review and has obtained significant grant funding in its early development, and we are delighted to be the syndication lead in this financing round.  Alzheimer's affects 4.5 million people in the United States today, with that number expected to exceed 12 million by 2050."

Funds raised in this round will support preclinical work required for IND candidate selection, and enable Cognition Therapeutics to further exploit novel molecular targets and pathways identified through the company's phenotypic screens.    

"Our drug leads selectively block the activity of the toxic oligomeric form of Abeta protein that interferes with normal learning and memory," said Susan Catalano, Ph.D., Cognition Therapeutics Chief Science Officer.  "Studies from the world's leading academic laboratories indicate that the memory deficits caused by this oligomeric protein are among the earliest changes seen in Alzheimer's and Mild Cognitive Impairment, the precursor to Alzheimer's. These studies indicate that blocking the effects of this protein may halt or reverse Alzheimer's disease."  

Cognition has developed a number of screening strategies to identify small molecules capable of blocking the central toxicity of proteins in Alzheimer's disease and other neurodegenerative diseases. These assays emphasize phenotypic or functional responses of mature primary neurons to the toxic proteins. Cognition's proprietary chemistry platform converts natural product molecular scaffolds into low molecular weight chemically stable drug-like molecules, and is thus a source of novel pharmacophores and valuable drug candidates.

"The registration of the company's proprietary biological screening approach with positive results in an animal model of Alzheimer's disease is a significant achievement," said Dr. Cynthia Lemere, Associate Professor of Neurology at Harvard University's Brigham & Women's Hospital and member of Cognition's Scientific Advisory Board.  "Cognition's scientific approach is unique in the industry and has generated exciting results that the Alzheimer's research community is watching closely.  Further development of these potentially disease-modifying drugs is very welcome," Dr. Lemere continued.

About Cognition

Cognition Therapeutics, Inc. is a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain and CNS. Toxic proteins play a crucial role in a large class of diseases, and there are currently no therapeutics available to prevent or block the destructive effects of toxic oligomeric proteins.  Cognition has leveraged its scientific expertise with these difficult targets to pioneer the use of proprietary assays that emphasize functional responses and proprietary medicinal chemistry to ensure novel, high quality small-molecule drug candidates for the treatment of these diseases.  www.cogrx.com

About Golden Seeds

Golden Seeds is one of the largest angel investing groups in the country.  With locations in New York, Boston, Philadelphia and San Francisco, Golden Seeds' 150 investors assist in all phases of the investment process, providing resources and expertise.


'/>"/>
SOURCE Cognition Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
2. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
3. ACTE Releases Paper Highlighting Policy Trend to Support Recognition of Academic Credit for CTE Classes
4. NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations
5. Mayuka Labs R&D Centre Gets DSIR Recognition
6. Childrens Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey
7. Consistency, Flexibility Key in Improving Rewards & Recognition Programs
8. Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx® in Cancer Treatment Options
9. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
10. Aratana Therapeutics Announces $20 Million Financing
11. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):